Current perspectives on oral contraceptive use

American Journal of Obstetrics and Gynecology

Volumn 185, Issue 2 SUPPL., 2001, Pages

  Burkman, Ronald T ^a,b   Collins, John A ^c   Shulman, Lee P ^d   Williams, J Kell ^e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF ILLINOIS   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Noncontraceptive health benefits; Oral contraceptives; Perimenopause

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

AMENORRHEA; ARTICLE; BONE DENSITY; BONE MINERAL; BREAKTHROUGH BLEEDING; BREAST CANCER; BREAST DISEASE; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; ECTOPIC PREGNANCY; ENDOMETRIUM CANCER; HEALTH STATUS; HEART INFARCTION; MENSTRUAL CYCLE; METRORRHAGIA; ORAL CONTRACEPTION; OVARY CANCER; OVARY CYST; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0034875323     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.117416     Document Type: Article

References (72)

1. Unintended pregnancy in the United States
2. Trends in contraceptive use in the United States: 1982-1995
3. The effect of extending the pill-free interval on follicular activity: Triphasic norgestimate/35 microgram ethinyl estradiol (EE) versus monophasic level onorgestrel/20 microgram EE
4. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol
5. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth
6. Ovarian function during low-dose oral contraceptive use
7. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 μg and 35 μg estrogen preparations
8. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol
9. Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol: Cycle control, lipid effects, and user satisfaction
10. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 μg/20 μg versus triphasic norethindrone/ethinylestradiol 500-750-1000 μg/ 35 μg: A multicenter, randomized, open-label study
11. Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol: A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg)
12. Treatment of menorrhagia
13. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status
14. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding
15. The reduction in risk of ovarian cancer associated with oral-contraceptive use
16. Endometrial cancer and combined oral contraceptives
17. Oral contraceptives and endometrial cancer
18. Combination oral contraceptive use and the risk of endometrial cancer
19. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives
20. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
21. Oral contraceptive and benign ovarian tumors
22. Benign ovarian cysts in England and Wales and in the United States
23. Noncontraceptive health benefits of oral steroidal contraceptives
24. Oral contraceptive use and risk of benign breast disease in a French case-control study of young women
25. Oral contraceptive use and risk of colorectal cancer
26. Large bowel cancer in women in relation to reproductive and hormonal factors: A case-control study
27. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer
28. The protective effect of the oral contraceptive pill on rheumatoid arthritis: An overview of the analytic epidemiological studies using meta-analysis
29. Oral contraception, paris, breast feeding, and severity of rheumatoid arthritis
30. Contraception and ectopic pregnancy risk
31. Pelvic inflammatory, disease: Trends in hospitalizations and office visits, 1979 through 1988
32. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease
33. The prevalence of acne on the basis of physical examination
34. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris
35. Hormonal correlates of acne and hirsutism
36. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
37. Epidemiology of osteoporosis: Predicting who is at risk
38. Bone-sparing properties of oral contraceptives
39. Oral contraceptives and bone-mineral density: A population-based study
40. Low-dose oral contraceptives and bone mineral density: An evidence-based analysis
41. Oral contraception: Past, present, and future perspectives
42. Cardiovascular disease and steroid hormone contraception: Report of a WHO Scientific Group
43. Oral contraceptives and nonfatal vascular disease
44. The risk of venous thromboembolism associated with low oestrogen oral contraceptives
45. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
46. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
47. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
48. Risk factors for fatal venous thromboembolism in young women: A case-control study
49. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
50. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
51. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
52. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
53. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
54. Resistance to activated protein C as a basis for venous thrombosis
55. Risk factors for acute myocardial infarction in women: Evidence from the Royal College of General Practitioners' oral contraceptive study
56. Implications of smoking and contraception use
57. Oral contraceptive use and the risk of myocardial infarction
58. Acute myocardial infarction and combined oral contraceptives: Results of an international, multicentre, case-control study
59. Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies
60. Stroke in users of low-dose oral contraceptives
61. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study
62. Migraine and stroke in young women: Case-control study
63. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study
64. Oral contraceptives and breast cancer - Resolution emerges
65. Breast cancer and hormonal contraceptives: Collaborative breast cancer reanalysis of individual data on 53 297 women with and 100 239 women without breast cancer from 54 epidemiological studies
66. Breast cancer and hormonal contraceptives: Further results
67. Hormonal contraception and breast cancer: Accounting for age at diagnosis